Categories
Change Password!
Reset Password!
In T2DM, combination therapy with SGLT2i and GLP-1 RAs delivers additive cardiovascular protection and superior metabolic control.
A major systematic review published in "Cureus" revealed that combining sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) remarkably improves cardiovascular (CV) and metabolic health in patients with type 2 diabetes mellitus (T2DM), marking a pivotal evolution in diabetes care.
Performed in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, researchers searched Web of Science, PubMed, Embase, and Scopus for relevant randomized controlled trials (RCTs). A total of 9 RCTs—including large CV outcome trials and mechanistic studies—met inclusion criteria. The outcomes assessed included major adverse cardiovascular events (MACE), heart failure (HF) hospitalization, renal outcomes, glycemic control (hemoglobin A1c [HbA1c] reduction), weight loss, systolic blood pressure reduction, and safety endpoints.
Post-hoc analyses revealed consistent additive cardioprotective effects:
The findings suggest independent and complementary mechanisms of action that translate into synergistic CV protection. Compared to monotherapy, combination therapy achieved:
These improvements reinforce the therapy’s potential for comprehensive cardiometabolic optimization in high-risk T2DM patients. No novel safety issues were detected, and the side-effect spectrum corresponded to known class effects, with manageable gastrointestinal and genital infection risks.
Hence, SGLT2i + GLP-1 RA therapy offers synergistic benefits across CV risk reduction, glycemic control, weight management, and blood pressure lowering—without a meaningful rise in safety concerns. However, researchers note that while current evidence is robust, definitive confirmation from prospective trials specifically designed to evaluate combination therapy remains .
Cureus
Cardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review
Dalia Tantawy et al.
Comments (0)